

CLAIMS

1. (Previously presented) A method for reducing a level of amyloid- β ($A\beta$) peptides in vivo, which method comprises administering an $A\beta$ level reducing dose of an estrogen compound to an animal, wherein the animal has an increased level of $A\beta$, and wherein the dose of the estrogen compound does not affect soluble APP levels.
2. (Original) The method according to claim 1, wherein the level of amyloid is a level of soluble amyloid in the brain of the animal.
3. (Original) The method according to claim 1, wherein the estrogen compound is 17-estradiol.
4. (Original) The method according to claim 1, wherein the estrogen compound is a composition of conjugated equine estrogen.
5. (Original) The method according to claim 1, wherein the $A\beta$ peptides comprise $A\beta_{42}$ and $A\beta_{40}$, which method further comprises reducing the ratio of $A\beta_{42}$ to $A\beta_{40}$.
6. (Original) The method according to claim 1, wherein the $A\beta$ peptides are $A\beta_{42}$ peptides.
7. (Withdrawn) A method for evaluating the ability of a test compound to reduce a level of $A\beta$ in vivo, which method comprises comparing the level of $A\beta$ of an orchidectomized non-human animal treated with the test compound to the level of $A\beta$ in an orchidectomized non-human control animal, wherein a reduction of the level of $A\beta$ in the animal treated with the test compound compared to the control animal indicates the ability of the test compound to reduce the level of $A\beta$ in vivo.
8. (Withdrawn) The method according to claim 7, wherein the animal is a gonadectomized animal.

9. (Withdrawn) The method according to claim 7, wherein the animal is a guinea pig.
10. (Withdrawn) The method according to claim 7, wherein the animal is a transgenic rodent that expresses a human amyloid precursor protein.
11. (Withdrawn) The method according to claim 10, wherein the animal is a double transgenic rodent that also expresses a presenilin protein.
12. (Withdrawn) The method according to claim 7, wherein the level of A β in brain is evaluated.
13. (Withdrawn) The method according to claim 7, wherein the test compound is an estrogen compound.
14. (Withdrawn) A method for evaluating the ability of a test compound to reduce a level of A β in vivo, which method comprises comparing the level of A β of an ovx non-human animal selected from the group consisting of a guinea pig and a transgenic rodent that expresses human amyloid precursor protein treated with the test compound to the level of A β in an ovx non-human control animal, wherein a reduction of the level of A β in the animal treated with the test compound compared to the control animal indicates the ability of the test compound to reduce the level of A in vivo.
15. (Withdrawn) A method for evaluating the ability of a test compound to reduce a ratio of A β 42 to A β 40 in vivo, which method comprises comparing a ratio of A β 42 to A β 40 in an orchidectomized non-human animal treated with a test compound to the ratio of A β 42 to A β 40 in an orchidectomized non-human control animal, wherein a reduction of the ratio of A β 42 to A β 40 in the animal treated with the test compound compared to the control animal indicates the ability of the test compound to reduce the ratio of A β 42 to A β 40 in vivo.
16. (Withdrawn) The method according to claim 15, wherein the animal is a gonadectomized animal.

17. (Withdrawn) The method according to claim 16, wherein the animal is a guinea pig.
18. (Withdrawn) The method according to claim 15, wherein the compound is an estrogen compound.
19. (Withdrawn) The method according to claim 18, wherein the estrogen compound is 17 β -estradiol.
20. (Previously presented) A method for delaying or reducing the likelihood of, or ameliorating, a disease or disorder associated with amyloidosis, which method comprises administering an A β level reducing dose of an estrogen compound to a subject who has an increased risk for developing or shows a symptom of the disease or disorder associated with amyloidosis, wherein the dose of the estrogen compound does not affect soluble APP levels.
21. (Original) The method according to claim 20, wherein the estrogen compound is 17 β -estradiol.
22. (Original) The method according to claim 20, wherein the estrogen compound is administered daily for at least ten days.
23. (Original) The method according to claim 20, wherein the estrogen compound is administered by a controlled release device.
24. (Original) The method according to claim 20, wherein the disease or disorder associated with amyloidosis is Alzheimer's disease.
25. (Original) The method according to claim 20, wherein a ratio of A β ₄₂ to A β ₄₀ is reduced in the subject.
26. (Withdrawn) A method for predicting an increased likelihood of amyloidosis in a subject, which method comprises observing a reduction in a level of an estrogen compound in the subject compared to a normal level or a level in the subject at an earlier time.

27. (Withdrawn) The method according to claim 26, wherein the estrogen compound is estrogen 17 β .

28. (Withdrawn) The method according to claim 26, wherein the estrogen compound is an aromatizable androgen.

29. (Withdrawn) The method according to claim 26, wherein the amyloidosis comprises deposition of A β peptides.

30. (Withdrawn) The method according to claim 29, wherein the amyloidosis comprises deposition of A β peptides.

31. (Previously presented) The method according to claim 4, wherein the dose of conjugated equine estrogen is selected from the group consisting of 0.3 mg, 0.625 mg, 1.25 mg, and 2.5 mg.

32. (Previously presented) The method according to claim 20, wherein the estrogen compound is a conjugated equine estrogen.

33. (Previously presented) The method according to claim 32, wherein the dose of conjugated equine estrogen is selected from the group consisting of 0.3 mg, 0.625 mg, 1.25 mg, and 2.5 mg.